$CDNA
CareDx Inc

2014 Q4 Form 10-K Financial Statement

#000156459016015429 Filed on March 29, 2016

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014 Q2
Revenue $7.952M $6.654M $6.776M
YoY Change 35.82% 14.63% 24.17%
Cost Of Revenue $2.200M $1.772M $2.403M
YoY Change -5.58% -29.18% 13.4%
Gross Profit $5.750M $4.882M $4.373M
YoY Change 63.35% 47.81% 31.01%
Gross Profit Margin 72.31% 73.37% 64.54%
Selling, General & Admin $3.980M $3.729M $3.926M
YoY Change 69.36% 25.68% 42.87%
% of Gross Profit 69.22% 76.38% 89.78%
Research & Development $1.300M $1.036M $792.0K
YoY Change 96.97% 55.09% -6.38%
% of Gross Profit 22.61% 21.22% 18.11%
Depreciation & Amortization $160.0K $130.0K $110.0K
YoY Change 33.33% 8.33% -35.29%
% of Gross Profit 2.78% 2.66% 2.52%
Operating Expenses $5.320M $5.261M $7.121M
YoY Change 76.16% -14.27% 24.65%
Operating Profit $430.0K $1.393M -$345.0K
YoY Change -14.0% -519.58% 34.77%
Interest Expense -$390.0K -$540.0K -$640.0K
YoY Change -29.09% 8.0% 18.52%
% of Operating Profit -90.7% -38.77%
Other Income/Expense, Net -$50.00K $355.0K $366.0K
YoY Change -90.57% -35600.0% -7420.0%
Pretax Income -$10.00K $1.213M -$623.0K
YoY Change -98.21% -246.14% -22.32%
Income Tax $0.00 $0.00 -$1.500M
% Of Pretax Income 0.0%
Net Earnings -$5.000K $1.213M $877.0K
YoY Change -99.11% -246.14% -209.35%
Net Earnings / Revenue -0.06% 18.23% 12.94%
Basic Earnings Per Share $0.00 $0.13 $0.87
Diluted Earnings Per Share $0.00 $0.12 $0.13
COMMON SHARES
Basic Shares Outstanding 11.80M 9.280M 1.013M
Diluted Shares Outstanding 11.80M 11.22M 6.940M

Balance Sheet

Concept 2014 Q4 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.40M $39.00M $7.900M
YoY Change 613.73%
Cash & Equivalents $36.43M $39.05M $7.872M
Short-Term Investments
Other Short-Term Assets $500.0K $700.0K $3.300M
YoY Change 66.67%
Inventory $686.0K $496.0K $614.0K
Prepaid Expenses
Receivables $2.700M $1.700M $1.700M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $40.35M $42.01M $13.53M
YoY Change 393.77%
LONG-TERM ASSETS
Property, Plant & Equipment $1.968M $2.049M $1.665M
YoY Change 26.72%
Goodwill $12.01M $12.01M $12.01M
YoY Change
Intangibles $6.650M $6.650M $6.650M
YoY Change
Long-Term Investments
YoY Change
Other Assets $25.00K $0.00 $0.00
YoY Change 1150.0%
Total Long-Term Assets $20.80M $20.85M $20.47M
YoY Change 1121.8%
TOTAL ASSETS
Total Short-Term Assets $40.35M $42.01M $13.53M
Total Long-Term Assets $20.80M $20.85M $20.47M
Total Assets $61.14M $62.86M $34.00M
YoY Change 519.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.128M $1.036M $1.741M
YoY Change 82.52%
Accrued Expenses $2.500M $2.600M $5.600M
YoY Change 38.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.961M $5.798M $10.43M
YoY Change 33.62%
Total Short-Term Liabilities $11.14M $11.12M $21.21M
YoY Change 46.65%
LONG-TERM LIABILITIES
Long-Term Debt $5.451M $6.930M $8.338M
YoY Change -50.05%
Other Long-Term Liabilities $28.00K $3.800M $5.100M
YoY Change
Total Long-Term Liabilities $5.479M $6.930M $8.338M
YoY Change -49.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.14M $11.12M $21.21M
Total Long-Term Liabilities $5.479M $6.930M $8.338M
Total Liabilities $19.84M $21.82M $35.46M
YoY Change -21.71%
SHAREHOLDERS EQUITY
Retained Earnings -$159.4M -$159.4M -$160.6M
YoY Change -0.49%
Common Stock $12.00K $12.00K $1.000K
YoY Change 1100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.30M $41.04M -$150.9M
YoY Change
Total Liabilities & Shareholders Equity $61.14M $62.86M $34.00M
YoY Change 519.27%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income -$5.000K $1.213M $877.0K
YoY Change -99.11% -246.14% -209.35%
Depreciation, Depletion And Amortization $160.0K $130.0K $110.0K
YoY Change 33.33% 8.33% -35.29%
Cash From Operating Activities -$720.0K -$3.660M $850.0K
YoY Change -21.74% -321.82% -342.86%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K -$170.0K -$140.0K
YoY Change 900.0% 750.0% 250.0%
Acquisitions
YoY Change
Other Investing Activities -$190.0K -$30.00K -$380.0K
YoY Change
Cash From Investing Activities -$590.0K -$200.0K -$520.0K
YoY Change 1375.0% 900.0% 1200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.300M 35.04M 2.700M
YoY Change 12900.0% -175300.0% -27100.0%
NET CHANGE
Cash From Operating Activities -720.0K -3.660M 850.0K
Cash From Investing Activities -590.0K -200.0K -520.0K
Cash From Financing Activities -1.300M 35.04M 2.700M
Net Change In Cash -2.610M 31.18M 3.030M
YoY Change 169.07% 1836.65% -857.5%
FREE CASH FLOW
Cash From Operating Activities -$720.0K -$3.660M $850.0K
Capital Expenditures -$400.0K -$170.0K -$140.0K
Free Cash Flow -$320.0K -$3.490M $990.0K
YoY Change -63.64% -308.98% -419.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001217234
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Trading Symbol
TradingSymbol
CDNA
CY2015 dei Entity Registrant Name
EntityRegistrantName
CareDx, Inc.
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12887000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
948000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
147000
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5451000
CY2015Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6650000
CY2015Q4 us-gaap Goodwill
Goodwill
12005000
CY2014Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1074000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1341000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
34362000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2425000
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6650000
CY2014Q4 us-gaap Goodwill
Goodwill
12005000
CY2015Q4 us-gaap Assets
Assets
55638000
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11966899
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29888000
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2015Q4 us-gaap Inventory Net
InventoryNet
766000
CY2014Q4 us-gaap Inventory Net
InventoryNet
686000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
542000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
40346000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1968000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49000
CY2014Q4 us-gaap Assets
Assets
61141000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1644000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2366000
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2892000
CY2015Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
242000
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1128000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1684000
CY2014Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1616000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11135000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1684000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
471000
CY2014Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5961000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
703000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1426000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2866000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10152000
CY2015Q2 dei Entity Public Float
EntityPublicFloat
48622431
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36431000
CY2015Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2367000
CY2014Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
2687000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
147000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173082000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159375000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
29494000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
41298000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55638000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61141000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
202564000
CY2015Q4 us-gaap Liabilities
Liabilities
26144000
CY2014Q4 us-gaap Liabilities
Liabilities
19843000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
200661000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
147000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3542000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1500000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.50
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5815928
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
505000
CY2014Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
241000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
142000
CY2015 cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
130000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
72000
CY2014 cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
727000
CY2013 cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
193000
CY2015 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
247000
CY2014 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
799000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
179000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11860885
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11902363
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11803970
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11902363
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11803970
CY2015 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
27881000
CY2014 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
25842000
CY2013 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
21672000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
263000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1464000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
426000
CY2015 us-gaap Revenues
Revenues
28144000
CY2014 us-gaap Revenues
Revenues
27306000
CY2013 us-gaap Revenues
Revenues
22098000
CY2015 us-gaap Cost Of Services
CostOfServices
10273000
CY2014 us-gaap Cost Of Services
CostOfServices
8541000
CY2013 us-gaap Cost Of Services
CostOfServices
9078000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9333000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3846000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3176000
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8349000
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6472000
CY2013 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5892000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12247000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8436000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4809000
CY2015 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-126000
CY2014 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-1239000
CY2013 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2015 us-gaap Operating Expenses
OperatingExpenses
40076000
CY2014 us-gaap Operating Expenses
OperatingExpenses
26056000
CY2013 us-gaap Operating Expenses
OperatingExpenses
22955000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-11932000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
1250000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-857000
CY2015 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1587000
CY2014 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2116000
CY2013 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2149000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-188000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-536000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13707000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-719000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-13707000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
781000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-3542000
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2013 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.50
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1010795
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11860885
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1010795
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9283001
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
223000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
46000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-225000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
203000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-147203000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
72000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-150673000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
149444000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5108000
CY2014 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
-539000
CY2014 cdna Issuance Of Common Stock Initial Public Offering
IssuanceOfCommonStockInitialPublicOffering
35511000
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
34000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
19000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
535000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1341000
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
90000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
796000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
512000
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
663000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2013 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
553000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2013 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
525000
CY2015 us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
CY2014 us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
-1500000
CY2013 us-gaap Other Noncash Income Tax Expense
OtherNoncashIncomeTaxExpense
0
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-320000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
417000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1318000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
80000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
168000
CY2013 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-58000
CY2015 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
823000
CY2014 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
310000
CY2013 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
4000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
489000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
510000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-19000
CY2015 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
682000
CY2014 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
298000
CY2013 us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
408000
CY2015 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
1000
CY2014 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
-2563000
CY2013 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
1259000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1083000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1240000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
364000
CY2013 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-91000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9752000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3350000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-546000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1199000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
733000
CY2013 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1199000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
98000
CY2015 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2014 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
600000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2015 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
25000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1333000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-98000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
39246000
CY2013 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2014 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3733000
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2015 us-gaap Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
0
CY2014 us-gaap Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
4982000
CY2013 us-gaap Proceeds From Issuance Of Subordinated Long Term Debt
ProceedsFromIssuanceOfSubordinatedLongTermDebt
0
CY2015 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
15625000
CY2014 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2013 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
0
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
46000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
CY2015 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
203000
CY2014 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2013 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
CY2015 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
11466000
CY2014 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
4528000
CY2013 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
58000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4408000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
35986000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-58000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6543000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31303000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-702000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5128000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5830000
CY2015 us-gaap Interest Paid Net
InterestPaidNet
1364000
CY2014 us-gaap Interest Paid Net
InterestPaidNet
1207000
CY2013 us-gaap Interest Paid Net
InterestPaidNet
1506000
CY2014 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
193000
CY2013 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2015 cdna Common Stock Issued For Acquisition
CommonStockIssuedForAcquisition
0
CY2014 cdna Common Stock Issued For Acquisition
CommonStockIssuedForAcquisition
14242000
CY2013 cdna Common Stock Issued For Acquisition
CommonStockIssuedForAcquisition
0
CY2015 cdna Conversion Of Convertible Preferred Stock To Common Stock At Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockAtInitialPublicOffering
0
CY2014 cdna Conversion Of Convertible Preferred Stock To Common Stock At Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockAtInitialPublicOffering
149444000
CY2013 cdna Conversion Of Convertible Preferred Stock To Common Stock At Initial Public Offering
ConversionOfConvertiblePreferredStockToCommonStockAtInitialPublicOffering
0
CY2015 cdna Conversion Of Convertible Preferred Stock Warrants To Common Stock Warrants
ConversionOfConvertiblePreferredStockWarrantsToCommonStockWarrants
0
CY2014 cdna Conversion Of Convertible Preferred Stock Warrants To Common Stock Warrants
ConversionOfConvertiblePreferredStockWarrantsToCommonStockWarrants
539000
CY2013 cdna Conversion Of Convertible Preferred Stock Warrants To Common Stock Warrants
ConversionOfConvertiblePreferredStockWarrantsToCommonStockWarrants
0
CY2015 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2014 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
5108000
CY2013 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2015 us-gaap Stock Issued1
StockIssued1
223000
CY2014 us-gaap Stock Issued1
StockIssued1
34000
CY2013 us-gaap Stock Issued1
StockIssued1
0
CY2015 cdna Debt Conversion Converted Instrument Common Stock Warrants Issued
DebtConversionConvertedInstrumentCommonStockWarrantsIssued
90000
CY2014 cdna Debt Conversion Converted Instrument Common Stock Warrants Issued
DebtConversionConvertedInstrumentCommonStockWarrantsIssued
0
CY2013 cdna Debt Conversion Converted Instrument Common Stock Warrants Issued
DebtConversionConvertedInstrumentCommonStockWarrantsIssued
0
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i)&#160;revenue recognition, (ii)&#160;the differences between amounts billed and estimated receipts from payers, (iii)&#160;the determination of the accruals for clinical studies, (iv)&#160;the determination of refunds to be requested by third-party payers, (v)&#160;the fair value of assets and liabilities, (vi)&#160;the valuation of warrants to purchase convertible preferred stock, (vii)&#160;the determination of fair value of the Company&#8217;s common stock, (viii)&#160;the contingent consideration in a business acquisition, (ix)&#160;the fair value of the embedded derivative associated with the subordinated convertible note, (x)&#160;the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xi)&#160;any impairment of long-lived assets including in-process technology and goodwill and (xii)&#160;legal contingencies. Actual results could differ from those estimates. </p></div>
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company&#8217;s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper, and various bank deposit accounts. These financial instruments were held in Company accounts at two financial institutions. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. For the years ended December&#160;31, 2015, 2014 and 2013, approximately 50%, 51% and 53%, respectively, of testing revenue was paid for by Medicare. No other payers represented more than 10% of testing revenue for these periods. At December&#160;31, 2015 and 2014, approximately 35% and 78%, respectively, of accounts receivable was due from Medicare. At December 31, 2015, approximately 21% of accounts receivable was due from Aetna. No other payer represented more than 10% of accounts receivable at December&#160;31, 2015 or 2014. </p></div>
CY2015 us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Revenue </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company&#8217;s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is more consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any milestones during the years ended December&#160;31, 2015, 2014 or 2013. </p></div>
CY2015 us-gaap Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
<div> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Advertising Expenses</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All advertising costs are expensed as incurred. Advertising expenses were insignificant during all of the periods presented.</p></div>
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 for 6.85
CY2015 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.145985401
CY2015 cdna Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2014-07-14
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
15800000
CY2015 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2014 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2015 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2014 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2013 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2015Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
155000
CY2014Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityCurrent
76000
CY2015Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
149000
CY2014Q4 cdna Debt Issuance And Discount Component Of Recognized Debt Liability Non Current
DebtIssuanceAndDiscountComponentOfRecognizedDebtLiabilityNonCurrent
11000
CY2015 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0
CY2014 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
364000
CY2013 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0
CY2015 cdna Fair Value Of Derivative Gain Loss On Derivative Net
FairValueOfDerivativeGainLossOnDerivativeNet
0
CY2014 cdna Fair Value Of Derivative Gain Loss On Derivative Net
FairValueOfDerivativeGainLossOnDerivativeNet
118000
CY2013 cdna Fair Value Of Derivative Gain Loss On Derivative Net
FairValueOfDerivativeGainLossOnDerivativeNet
0
CY2015 cdna Derivative Gain Loss On Extinguishment Of Debt
DerivativeGainLossOnExtinguishmentOfDebt
0
CY2014 cdna Derivative Gain Loss On Extinguishment Of Debt
DerivativeGainLossOnExtinguishmentOfDebt
120000
CY2013 cdna Derivative Gain Loss On Extinguishment Of Debt
DerivativeGainLossOnExtinguishmentOfDebt
0
CY2015 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13707000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
907000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3542000
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
2972051
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
134341
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
360681
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1984586
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
753322
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6250853
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
525000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
2552000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-1464000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Instruments Classified In Shareholders Equity Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisInstrumentsClassifiedInShareholdersEquityTransfersNet
-539000
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1074000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-126000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
948000
CY2015 cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
237000
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
277000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
529000
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
409000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14298000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13060000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11873000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11092000
CY2015 us-gaap Adjustment For Amortization
AdjustmentForAmortization
79000
CY2014 us-gaap Adjustment For Amortization
AdjustmentForAmortization
59000
CY2013 us-gaap Adjustment For Amortization
AdjustmentForAmortization
26000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
880000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
273000
CY2015Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
426000
CY2014Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
318000
CY2015Q4 cdna Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
163000
CY2014Q4 cdna Accrued Over Payments And Refunds
AccruedOverPaymentsAndRefunds
146000
CY2015Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
756000
CY2014Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
144000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
258000
CY2014Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
202000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
71000
CY2014Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
70000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
338000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
463000
CY2015 cdna Operating Leases Expiration Month Year
OperatingLeasesExpirationMonthYear
2020-12
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
75000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
55000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
16000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
5000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
0
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
151000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
23000
CY2015Q4 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
128000
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
57000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1291000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1348000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1376000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1404000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1432000
CY2015Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6851000
CY2012 us-gaap Proceeds From License Fees Received
ProceedsFromLicenseFeesReceived
1000000
CY2012 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
250000
CY2014 us-gaap Licenses Revenue
LicensesRevenue
1100000
CY2013 us-gaap Licenses Revenue
LicensesRevenue
328000
CY2014 us-gaap Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
626000
CY2013 us-gaap Amortization Of Deferred Leasing Fees
AmortizationOfDeferredLeasingFees
187000
CY2014 us-gaap Reimbursement Revenue
ReimbursementRevenue
16000
CY2013 us-gaap Reimbursement Revenue
ReimbursementRevenue
141000
CY2014 cdna Termination Fee
TerminationFee
500000
CY2013 cdna Termination Fee
TerminationFee
0
CY2015 cdna Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
250000
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
344000
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
387500
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
503000
CY2013Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
467000
CY2015 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
46000
CY2014 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
36000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
221000
CY2013 us-gaap Royalty Revenue
RoyaltyRevenue
94000
CY2015Q4 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2014Q4 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
54000
CY2012Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2012Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
10333833
CY2012Q3 cdna Debt Instrument Termination Fee Amount
DebtInstrumentTerminationFeeAmount
875000
CY2012 us-gaap Interest Expense Debt
InterestExpenseDebt
628000
CY2012Q3 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
3432260
CY2015 us-gaap Debt Instrument Collateral Fee
DebtInstrumentCollateralFee
150000
CY2015 us-gaap Debt Instrument Date Of First Required Payment1
DebtInstrumentDateOfFirstRequiredPayment1
2014-03-01
CY2015 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
566822
CY2015Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0995
CY2015Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
1275000
CY2015 us-gaap Debt Instrument Description
DebtInstrumentDescription
The Company agreed to issue to the lender detachable warrants to purchase shares of the Company’s common stock upon the drawdown of each advance in an amount equal to 1.5% of the amount drawn, divided by the exercise price per share for that tranche.
CY2015Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
75000
CY2015 us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
Interest-only payments for 18 months followed by 30 equal monthly principal and interest payments
CY2015 cdna Initial Public Offering Date Of Completion
InitialPublicOfferingDateOfCompletion
2014-07-22
CY2014Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
510777
CY2014Q3 cdna Amortization Of Debt Discount
AmortizationOfDebtDiscount
256000
CY2015Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
120000
CY2015Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
20000000
CY2015 us-gaap Debt Instrument Description Of Variable Rate Basis
DebtInstrumentDescriptionOfVariableRateBasis
Draw A bears interest at a daily floating rate equal to 2.00%, plus the greater of (i) 3.25% or (ii) the prime rate published by the lender
CY2015Q1 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0200
CY2015 us-gaap Line Of Credit Facility Initiation Date1
LineOfCreditFacilityInitiationDate1
2015-01-30
CY2015 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-12-01
CY2015 cdna Prepayment Penalty
PrepaymentPenalty
0.00
CY2015Q1 cdna Estimated Fair Value Of Warrants
EstimatedFairValueOfWarrants
90000
CY2015 us-gaap Default Longterm Debt Description Of Violation Or Event Of Default
DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault
Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.
CY2015 cdna Percentage Of Default Interest Payment
PercentageOfDefaultInterestPayment
0.05
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
180266
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4081
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7247
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
149563
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
332995
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
940884
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
585345
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Assumed In Acquisition
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAssumedInAcquisition
0
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
20591
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
13781
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
722906
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
357075
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
652078
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
77660
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
5329
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
510892
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
619906
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
212
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
466965
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved For Available For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedForAvailableForIssuance
0
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod
23229
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
9363
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1031804
CY2015 cdna Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Reserved For Available For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedForAvailableForIssuance
0
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23576
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1577317
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.67
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.48
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.55
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.33
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.73
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.99
CY2014 cdna Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
0
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.76
CY2014 cdna Share Based Compensation Arrangements By Share Based Payment Award Options Shares Assumed From Acquisition Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsSharesAssumedFromAcquisitionWeightedAverageExercisePrice
2.06
CY2015 cdna Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0.000
CY2014 cdna Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0.058
CY2013 cdna Effective Income Tax Rate Reconciliation Interest Expense
EffectiveIncomeTaxRateReconciliationInterestExpense
0.000
CY2015 cdna Effective Income Tax Rate Reconciliation Liability Contingent For Unconsolidated Subsidiary Percent
EffectiveIncomeTaxRateReconciliationLiabilityContingentForUnconsolidatedSubsidiaryPercent
0.000
CY2014 cdna Effective Income Tax Rate Reconciliation Liability Contingent For Unconsolidated Subsidiary Percent
EffectiveIncomeTaxRateReconciliationLiabilityContingentForUnconsolidatedSubsidiaryPercent
0.382
CY2013 cdna Effective Income Tax Rate Reconciliation Liability Contingent For Unconsolidated Subsidiary Percent
EffectiveIncomeTaxRateReconciliationLiabilityContingentForUnconsolidatedSubsidiaryPercent
0.000
CY2015 cdna Effective Income Tax Rate Reconciliation Acquisition Costs
EffectiveIncomeTaxRateReconciliationAcquisitionCosts
0.032
CY2014 cdna Effective Income Tax Rate Reconciliation Acquisition Costs
EffectiveIncomeTaxRateReconciliationAcquisitionCosts
0.367
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.14
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.36
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.74
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.36
CY2015 cdna Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
0
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.09
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.94
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.13
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
10.36
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.87
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
89000
CY2015Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1577317
CY2015 cdna Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding And Exercisable Options Weighted Average Remaining Contractual Term
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingAndExercisableOptionsWeightedAverageRemainingContractualTerm
P7Y11M1D
CY2015Q4 cdna Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding And Exercisable Options Weighted Average Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingAndExercisableOptionsWeightedAverageExercisePrice
6.87
CY2015Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
679993
CY2015 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
5.75
CY2015Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
897324
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1577317
CY2015Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
7.71
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.87
CY2015 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y6M29D
CY2015 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y11M12D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y11M1D
CY2015Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
1788000
CY2015Q4 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
435000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2223000
CY2015Q4 us-gaap Share Price
SharePrice
6.40
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.53
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.81
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.21
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10200000
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M18D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1100000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1341000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
535000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
72000
CY2015 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2014 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2013 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
CY2015 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2014 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2013 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.019
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.095
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.114
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.311
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1.906
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.086
CY2015 cdna Effective Income Tax Rate Reconciliation Change In Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefits
0.000
CY2014 cdna Effective Income Tax Rate Reconciliation Change In Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefits
0.000
CY2013 cdna Effective Income Tax Rate Reconciliation Change In Unrecognized Tax Benefits
EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTaxBenefits
-0.084
CY2015 cdna Effective Income Tax Rate Reconciliation Preferred Stock Warrant Revaluation
EffectiveIncomeTaxRateReconciliationPreferredStockWarrantRevaluation
0.000
CY2014 cdna Effective Income Tax Rate Reconciliation Preferred Stock Warrant Revaluation
EffectiveIncomeTaxRateReconciliationPreferredStockWarrantRevaluation
0.007
CY2013 cdna Effective Income Tax Rate Reconciliation Preferred Stock Warrant Revaluation
EffectiveIncomeTaxRateReconciliationPreferredStockWarrantRevaluation
0.050
CY2013 cdna Effective Income Tax Rate Reconciliation Acquisition Costs
EffectiveIncomeTaxRateReconciliationAcquisitionCosts
0.000
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.022
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.013
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.006
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
2.088
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
65957000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
63116000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4533000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4065000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
1125000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
942000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
698000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
551000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
72313000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
68674000
CY2015Q4 cdna Deferred Tax Liabilities Assets Net Property Plant And Equipment
DeferredTaxLiabilitiesAssetsNetPropertyPlantAndEquipment
-95000
CY2014Q4 cdna Deferred Tax Liabilities Assets Net Property Plant And Equipment
DeferredTaxLiabilitiesAssetsNetPropertyPlantAndEquipment
8000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2355000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
877000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
1213000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-5000
CY2014Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2349000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2260000
CY2014Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2357000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
70053000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
66317000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3700000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-1900000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2054000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2196000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1159000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
372000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
83000
CY2013 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
177000
CY2015 cdna Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
5000
CY2014 cdna Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-225000
CY2013 cdna Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
860000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2431000
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
2000000
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1600000
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2015Q1 us-gaap Revenues
Revenues
7216000
CY2015Q2 us-gaap Revenues
Revenues
7129000
CY2015Q3 us-gaap Revenues
Revenues
7151000
CY2015Q4 us-gaap Revenues
Revenues
6648000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2272000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3185000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3489000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-4761000
CY2015Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2015Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2015Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
CY2015Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2015Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2015Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.40
CY2015Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11814467
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11835405
CY2015Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11890057
CY2015Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11902325
CY2015Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11814467
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11835405
CY2015Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11890057
CY2015Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11902325
CY2014Q1 us-gaap Revenues
Revenues
5924000
CY2014Q2 us-gaap Revenues
Revenues
6776000
CY2014Q3 us-gaap Revenues
Revenues
6654000
CY2014Q4 us-gaap Revenues
Revenues
7952000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-1304000
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.87
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2014Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
CY2014Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1011980
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1013128
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9279649
CY2014Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11802241
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1011980
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6939568
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11219377
CY2014Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11802241

Files In Submission

Name View Source Status
0001564590-16-015429-index-headers.html Edgar Link pending
0001564590-16-015429-index.html Edgar Link pending
0001564590-16-015429.txt Edgar Link pending
0001564590-16-015429-xbrl.zip Edgar Link pending
cdna-10k_20151231.htm Edgar Link pending
cdna-20151231.xml Edgar Link completed
cdna-20151231.xsd Edgar Link pending
cdna-20151231_cal.xml Edgar Link unprocessable
cdna-20151231_def.xml Edgar Link unprocessable
cdna-20151231_lab.xml Edgar Link unprocessable
cdna-20151231_pre.xml Edgar Link unprocessable
cdna-ex231_483.htm Edgar Link pending
cdna-ex311_6.htm Edgar Link pending
cdna-ex312_7.htm Edgar Link pending
cdna-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
greizgxi4gxm000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending